Healthcare, Financials Dec 21, 2021 12:29 PM (GMT+8) · EqualOcean
Financial Associated Press, Dec. 21 - China biopharmaceutical announced on the Hong Kong stock exchange that the company's second-generation highly selective P2X3 inhibitor (tcr1672) has obtained the drug clinical trial approval notice issued by the China food and Drug Administration and agreed to carry out the clinical trial of refractory chronic cough (RCC) in China.
Related companies: